Analyst firms · Needham · BIIB

Needham BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Needham rates Biogen Inc. (BIIB) Buy with a $255 price target, as of its latest action on Jun 8, 2026. It has published 9 rating actions on BIIB since September 2021, including 1 upgrade and 1 downgrade. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Needham's $255 is 10% above that.

Current rating
Buy
Price target
$255
Median target, all firms
$231.50
Actions on BIIB
9

Needham price target on BIIB

$400$328$25520222023202420252026
Needham price target on BIIB, each point a stated target, September 2021 to June 2026.

Every Needham rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Needham and BIIB

What is Needham's price target for BIIB?
Needham's latest stated price target for Biogen Inc. (BIIB) is $255, from its action on Jun 8, 2026.
What is Needham's rating on BIIB?
Needham rates BIIB Buy, a bullish rating, as of Jun 8, 2026.
When did Needham last change its view on BIIB?
On Jun 8, 2026, Needham upgrades to Buy from Hold, price target $255.
How does Needham's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Needham's $255 is 10% above that.

More BIIB rating histories

All Needham ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.